For the quarter ending 2025-09-30, TRAW had -$6,661K decrease in cash & cash equivalents over the period. -$6,596K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -3,962 | 20,575 |
| Change in fair value of warrant liability | 3 | -26,659 |
| Depreciation and amortization | 15 | 2 |
| Stock-based compensation | 135 | 266 |
| Receivables | 668 | -442 |
| Prepaid expenses and other current assets | 248 | -882 |
| Accounts payable | 524 | -3,605 |
| Accrued expenses and other current liabilities | 189 | -528 |
| Deferred revenue | 1 | -2,791 |
| Net cash used in operating activities | -4,011 | -11,416 |
| Cash paid for acquisition, net of cash acquired | 2,585 | - |
| Net cash used in investing activities | -2,585 | - |
| Proceeds from sale of common stock pursuant to the atm | 116 | 3,379 |
| Payment of offering costs | 178 | 287 |
| Proceeds from exercised prefunded warrants | 0 | 16 |
| Net cash provided by financing activities | -62 | 3,108 |
| Effect of foreign currency translation on cash | -3 | 51 |
| Net decrease in cash and cash equivalents | -6,661 | -8,257 |
| Cash and cash equivalents at beginning of period | 21,338 | - |
| Cash and cash equivalents at end of period | 6,420 | - |
Traws Pharma, Inc. (TRAW)
Traws Pharma, Inc. (TRAW)